These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 36096994)

  • 1. Corrigendum to "A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors" [Int. Immunopharmacol. 108 (2022) 108775].
    Morimoto K; Yamada T; Morimoto Y; Ishikawa T; Asai J; Fujihara A; Arai A; Katoh N; Ukimura O; Hirano S; Itoh Y; Takayama K
    Int Immunopharmacol; 2022 Nov; 112():109232. PubMed ID: 36096994
    [No Abstract]   [Full Text] [Related]  

  • 2. A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors.
    Morimoto K; Yamada T; Morimoto Y; Ishikawa T; Asai J; Fujihara A; Arai A; Katoh N; Ukimura O; Hirano S; Itoh Y; Takayama K
    Int Immunopharmacol; 2022 Jul; 108():108775. PubMed ID: 35436741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
    Hall E; Zhang J; Kim EJ; Hwang G; Chu G; Bhatia S; Reddy S
    Cancer Med; 2020 Mar; 9(6):2106-2112. PubMed ID: 31994335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
    Torasawa M; Yoshida T; Yagishita S; Shimoda Y; Shirasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
    Lung Cancer; 2022 May; 167():49-57. PubMed ID: 35397298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
    Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA.
    Laliberté F; Raut M; Yang X; Germain G; Nahar A; Desai KD; MacKnight SD; Sen SS; Duh MS
    Target Oncol; 2021 Jan; 16(1):85-94. PubMed ID: 33284424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
    Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
    Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC.
    Cui P; Li R; Huang Z; Wu Z; Tao H; Zhang S; Hu Y
    Sci Rep; 2020 Aug; 10(1):13160. PubMed ID: 32753702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer.
    Franchi M; Pellegrini G; Corrao G
    Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
    Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
    Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow up survey for implementation of fixed-dosing of monoclonal antibodies.
    Heinhuis KM; Beijnen JH; Hendrikx JJMA
    Int J Clin Pharm; 2020 Feb; 42(1):3-6. PubMed ID: 32026351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.
    Al-Showbaki L; Nadler MB; Desnoyers A; Almugbel FA; Cescon DW; Amir E
    J Cancer; 2021; 12(14):4372-4378. PubMed ID: 34093837
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer.
    Burgos-San José A; Colomer-Aguilar C; Martínez-Caballero D; Massutí-Sureda B
    Farm Hosp; 2021 Apr; 45(3):121-125. PubMed ID: 33941055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum to "Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials" [Int. Immunopharmacol. 62 (2018) 46-58].
    Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
    Int Immunopharmacol; 2018 Nov; 64():432. PubMed ID: 30220547
    [No Abstract]   [Full Text] [Related]  

  • 17. Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting.
    Kato R; Ikarashi D; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Tokuyama R; Tamai K; Harigai N; Nakazaki Y; Obara W
    Transl Oncol; 2020 Jun; 13(6):100771. PubMed ID: 32375081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and Toxicity of Checkpoint Inhibitors for Solid Tumor Treatment in a Veteran Population.
    Gordon SE; Bryan WE; Hammond JM
    Fed Pract; 2021 Aug; 38(Suppl 3):S46-S51. PubMed ID: 34733095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.